chevron_leftBack
As of 24 April 2025, Revvity, Inc. has a market cap of $11.27B USD, ranking #1546 globally and #569 in the United States. It ranks #135 in the Healthcare sector, and #17 in the Diagnostics & Research industry.
Key Stats
Enterprise Value
$13.44BUSD
Net Income (TTM)
$270.39MUSD
Company Profile
warningChart data may be delayed
1d |
1w |
1m |
3m |
6m |
YTD |
1y |
3y |
5y |
1.6%
|
0.1%
|
-13%
|
-24%
|
-21%
|
-16%
|
-6.9%
|
-39%
|
9.7%
|
Upcoming Earnings
Earnings Date
Mon, Apr 28
Earnings Time
sunny
Before Open
EPS Estimate
$0.9600
-2% yoy
Revenue Estimate
$662.3M
1.9% yoy
Markets
Exchange |
Ticker |
Price |
Quotes |
|
RVTY
Revvity Inc
ISIN: US7140461093
Shares Out.:
Shares Outstanding:
120.147M1
Shares Float:
119.643M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
93.82 USD
|
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
|
0KHE
Revvity Inc
ISIN: US7140461093
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
92.75 USD
|
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Revvity, Inc.
Revvity, Inc. provides health sciences solutions, technologies, and services worldwide. The company’s Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and DNA sequencing services. Its Diagnostics segment offers instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. It also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for use in oncology, screening newborns for rare genetic conditions, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific, BioQule, BoBs, chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPatternTM, Evolution Evoya, explorer, Fontus, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Omni Bead Ruptor, Omni Bead Ruptor Elite, Omni Tip, Pannoramic, Panthera Puncher, PG-Seq, PG-Find, PreNAT II, Prime, Protein Clear, ProteinEXact, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord, VICTOR2D, and Zephyr brands. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Similar Companies